Gulf International Bank UK Ltd Cuts Holdings in Hologic, Inc. (NASDAQ:HOLX)

Gulf International Bank UK Ltd decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 1.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 19,223 shares of the medical equipment provider’s stock after selling 198 shares during the period. Gulf International Bank UK Ltd’s holdings in Hologic were worth $1,385,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. General Partner Inc. purchased a new position in Hologic in the fourth quarter valued at $26,000. Venturi Wealth Management LLC increased its holdings in Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 261 shares in the last quarter. First Horizon Advisors Inc. increased its holdings in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares in the last quarter. Covestor Ltd increased its holdings in Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after buying an additional 133 shares in the last quarter. Finally, Loomis Sayles & Co. L P increased its holdings in Hologic by 29.3% in the third quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider’s stock valued at $66,000 after buying an additional 183 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

HOLX opened at $63.38 on Friday. The firm has a market capitalization of $14.22 billion, a PE ratio of 19.99, a PEG ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a twelve month low of $62.69 and a twelve month high of $84.67. The firm’s 50-day moving average price is $69.16 and its 200 day moving average price is $75.94. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, sell-side analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Wolfe Research assumed coverage on shares of Hologic in a research note on Friday, December 13th. They set a “peer perform” rating for the company. Stephens reissued an “overweight” rating and set a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. Mizuho cut their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. UBS Group boosted their target price on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Finally, Needham & Company LLC cut shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price for the company. in a research note on Monday, February 3rd. Ten analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $85.77.

Insider Buying and Selling at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.88% of the stock is currently owned by company insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.